Back to top

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of ...

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease | CGTX Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Cognition Therapeutics, Inc. (CGTX)